SMTI
Premium GrowerSanara MedTech Inc. · Healthcare · United States · $301M cap · $4.5M/day traded
$31.61 -0.2% · close 11 Nov · scored 12 Nov
Premium Grower: Strong business with the market behind it, priced at a premium.
As of 12 Nov 2026, the MoatMap Score for Sanara MedTech Inc. (SMTI) is 61/100, ranked against 25,000+ stocks in 38 markets (Quality 58, Value 24, Momentum 75, each scored against its sector).
Does the score work? Each tenth of the ranking, tracked monthly. See the record →
ABOUT SANARA MEDTECH INC.
Read
Sanara MedTech Inc. develops and commercializes advanced wound care and surgical tissue repair products, including biologics and sophisticated wound care solutions. The company offers a proprietary product portfolio rooted in regenerative medicine, supported by clinical evidence for efficacy and a specialized sales force. Sanara MedTech is a niche player in the growing wound care market, focusing on innovative solutions for complex medical cases.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 24.1M | 45.8M | 65.0M | 86.7M | 103.1M | 43.8% | 109.8M | 116.6M | 133.2M | 13.6% |
| EPS | -1.08 | -1.00 | -0.52 | -1.14 | -4.36 | — | — | — | — | — |
| Shares | 7.7M | 8.3M | 8.5M | 8.8M | 8.9M | +16.5% | 9.2M | — | — | — |
| Debt | 0.4M | 0.8M | 11.8M | 32.3M | 48.2M | 226.2% | 48.5M | — | — | — |
| Equity | 30.6M | 41.8M | 44.8M | 39.4M | 5.9M | -33.6% | — | — | — | — |
| Op CF | -4.8M | -5.6M | -3.2M | -23.8K | 6.8M | — | 5.7M | — | — | — |
| Inv CF | -5.3M | -3.5M | -10.2M | -6.6M | -15.0M | — | — | — | — | — |
| Fin CF | 28.3M | -0.6M | 9.6M | 17.4M | 8.9M | — | — | — | — | — |
Above its 200-day average and 11% below its 52-week high.
Swung more than 71% of stocks we rank over the past year (volatility 57% a year).
How this is worked out
The MoatMap Score weighs the business, its price and its trend. The price check reads only the chart: the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SMTI are excluded.
| Ticker | Company | Mkt Cap | Score |
|---|---|---|---|
| SMTI | Sanara MedTech Inc.(you) | $301M | 61 |
| OSUR | OraSure Technologies, Inc. | $285M | 42 |
| PDEX | Pro-Dex, Inc. | $201M | 89 |
| ANGO | AngioDynamics, Inc. | $520M | 35 |
| UTMD | Utah Medical Products, Inc. | $236M | 95 |
| KRMD | KORU Medical Systems, Inc. | $146M | 35 |
| EMBC | Embecta Corp. | $380M | 97 |
| XRAY | DENTSPLY SIRONA Inc. | $1.9B | 52 |
| AZTA | Azenta, Inc. | $1.6B | 48 |
| ATRC | AtriCure, Inc. | $3.0B | 61 |
Peer medians: ROE -31.0% · P/E 25.9x · Gross margin 62.7%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.